Rochelle Strenger

565 total citations
19 papers, 414 citations indexed

About

Rochelle Strenger is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Rochelle Strenger has authored 19 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Cancer Research and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Rochelle Strenger's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (9 papers) and HER2/EGFR in Cancer Research (6 papers). Rochelle Strenger is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (9 papers) and HER2/EGFR in Cancer Research (6 papers). Rochelle Strenger collaborates with scholars based in United States and Switzerland. Rochelle Strenger's co-authors include Lyndsay N. Harris, Mathew J. Ellis, Charles L. Vogel, Robert D. Legare, Eric P. Winer, Beth Overmoyer, Raquel Nunes, Susana M. Campos, Craig A. Bunnell and P. Kelly Marcom and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Rochelle Strenger

18 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rochelle Strenger United States 6 370 164 131 60 46 19 414
R. Lambert-Falls United States 6 544 1.5× 102 0.6× 261 2.0× 98 1.6× 60 1.3× 9 578
Jean-Yves Leroy Belgium 6 396 1.1× 158 1.0× 104 0.8× 49 0.8× 223 4.8× 11 465
V. Diéras France 8 261 0.7× 84 0.5× 38 0.3× 65 1.1× 53 1.2× 25 321
M. Byakhov United States 4 376 1.0× 240 1.5× 136 1.0× 66 1.1× 53 1.2× 6 451
Carmine Valenza Italy 10 185 0.5× 87 0.5× 65 0.5× 86 1.4× 76 1.7× 47 311
José Roberto Freitas Rossari Belgium 6 273 0.7× 157 1.0× 27 0.2× 107 1.8× 68 1.5× 8 329
Amna Sheri United Kingdom 9 200 0.5× 147 0.9× 23 0.2× 72 1.2× 61 1.3× 20 306
Kris Jacobson United States 7 185 0.5× 142 0.9× 52 0.4× 88 1.5× 180 3.9× 8 315
Gianni Simone Italy 10 235 0.6× 162 1.0× 35 0.3× 52 0.9× 144 3.1× 15 357
Chiara Fabbroni Italy 7 170 0.5× 43 0.3× 68 0.5× 117 1.9× 86 1.9× 22 272

Countries citing papers authored by Rochelle Strenger

Since Specialization
Citations

This map shows the geographic impact of Rochelle Strenger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rochelle Strenger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rochelle Strenger more than expected).

Fields of papers citing papers by Rochelle Strenger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rochelle Strenger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rochelle Strenger. The network helps show where Rochelle Strenger may publish in the future.

Co-authorship network of co-authors of Rochelle Strenger

This figure shows the co-authorship network connecting the top 25 collaborators of Rochelle Strenger. A scholar is included among the top collaborators of Rochelle Strenger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rochelle Strenger. Rochelle Strenger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Graff, Stephanie L., et al.. (2023). Evaluating Patient Experience in a Multidisciplinary Breast Cancer Clinic: A Prospective Study. Journal of Women s Health. 33(1). 39–44.
2.
Graff, Stephanie L., et al.. (2022). Patient experience with breast cancer care delivered in a multidisciplinary clinic.. Journal of Clinical Oncology. 40(16_suppl). e13506–e13506. 2 indexed citations
3.
Dizon, Don S., Katina Robison, Jason T. Machan, et al.. (2022). Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976).. Journal of Clinical Oncology. 40(16_suppl). 5598–5598. 2 indexed citations
4.
Strenger, Rochelle, Robert D. Legare, Mary Anne Fenton, et al.. (2021). Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study. Breast Cancer Research and Treatment. 189(1). 93–101. 2 indexed citations
5.
Strenger, Rochelle, et al.. (2020). Low-grade adenosquamous carcinoma of the breast: A case with pathogenic germline mutation in the BRIP1 gene. SHILAP Revista de lepidopterología. 22. 200444–200444. 1 indexed citations
6.
Strenger, Rochelle, Robert D. Legare, Mary Anne Fenton, et al.. (2020). Abstract P2-16-19: Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H+BC): A Brown University oncology group (BrUOG) study. Cancer Research. 80(4_Supplement). P2–16. 1 indexed citations
7.
Sinclair, Natalie, Maysa Abu‐Khalaf, George Somlo, et al.. (2013). Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study.. Journal of Clinical Oncology. 31(15_suppl). 619–619. 6 indexed citations
8.
9.
Rizack, Tina, Maysa Abu‐Khalaf, Robert D. Legare, et al.. (2010). Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data.. Journal of Clinical Oncology. 28(15_suppl). e11010–e11010. 2 indexed citations
10.
Sikov, William M., Don S. Dizon, Rochelle Strenger, et al.. (2009). Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. Journal of Clinical Oncology. 27(28). 4693–4700. 85 indexed citations
11.
Dizon, Don S., et al.. (2007). Clinical characteristics of women presenting with skin-only recurrence of breast cancer. The American Journal of Surgery. 194(4). 494–496. 1 indexed citations
12.
Theall, K. P., et al.. (2005). Gemcitabine and capecitabine in metastatic breast cancer (MBC): A Brown University Oncology Group (BrUOG) phase II study. Journal of Clinical Oncology. 23(16_suppl). 785–785. 3 indexed citations
13.
Dizon, Don S., et al.. (2005). Kids Talk: implementation of a safe place for the children of caregivers with cancer. Journal of Clinical Oncology. 23(16_suppl). 8189–8189. 2 indexed citations
14.
Fenton, Mary Anne, Don S. Dizon, Jennifer Gass, et al.. (2005). Neoadjuvant q4week carboplatin and weekly paclitaxel ± trastuzumab in resectable and locally advanced breast cancer: A Brown University Oncology Group (BrUOG) study. Journal of Clinical Oncology. 23(16_suppl). 759–759. 3 indexed citations
15.
16.
Legare, Robert D. & Rochelle Strenger. (2002). Adjuvant therapy in breast cancer. Obstetrics and Gynecology Clinics of North America. 29(1). 201–208. 7 indexed citations
17.
Lopez, Francisco, et al.. (2000). B‐cell bradycardia: Carotid sinus massage by a high‐grade lymphoma. American Journal of Hematology. 64(3). 232–232. 1 indexed citations
18.
Akerley, Wallace, et al.. (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.. PubMed. 24(5 Suppl 17). S17–90. 28 indexed citations
19.
Strenger, Rochelle, et al.. (1995). Retrospective diagnosis of sickle cell-hemoglobin C disease and parvovirus infection by molecular DNA analysis of postmortem tissue. Human Pathology. 26(12). 1375–1378. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Lambert-Falls Breakdown of academic impact, for papers by Jean-Yves Leroy Breakdown of academic impact, for papers by V. Diéras Breakdown of academic impact, for papers by M. Byakhov Breakdown of academic impact, for papers by Carmine Valenza Breakdown of academic impact, for papers by José Roberto Freitas Rossari Breakdown of academic impact, for papers by Amna Sheri Breakdown of academic impact, for papers by Kris Jacobson Breakdown of academic impact, for papers by Gianni Simone Breakdown of academic impact, for papers by Chiara Fabbroni
Rankless by CCL
2026